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Abstract
Background: Many cancer survivors suffer a range of physical and psychological symptoms which may persist for 
months or years after cessation of treatment. Despite the known benefits of exercise and its potential to address many 
of the adverse effects of treatment, the role of exercise as well as optimum duration, frequency, and intensity in this 
population has yet to be fully elucidated. Many cancer rehabilitation programmes presented in the literature are very 
long and have tight eligibility criteria which make them non-applicable to the majority of cancer survivors. This paper 
presents the protocol of a novel 8-week intervention which aims to increase fitness, and address other physical 
symptoms in a heterogeneous cancer survivor population.
Methods/design: The aim is to recruit 64 cancer survivors 2-6 months after completion of chemotherapy, usually 
adjuvant, with curative intent. Subjects will be recruited through oncology clinics in a single institution and 
randomised to usual care or an exercise intervention. The exercise intervention consists of two specifically tailored 
supervised moderate intensity aerobic exercise sessions weekly over 8-weeks. All participants will be assessed at 
baseline (0 weeks), at the end of the intervention (8 weeks), and at 3-month follow-up. The primary outcome measure 
is fitness, and secondary patient-related outcome measures include fatigue, quality of life, and morphological 
outcomes. A further secondary outcome is process evaluation including adherence to and compliance with the 
exercise program.
Discussion: This study will provide valuable information about the physical outcomes of this 8-week supervised 
aerobic programme. Additionally, process information and economic evaluation will inform the feasibility of 
implementing this program in a heterogeneous population post cessation of chemotherapy.
Trial Registration: NCT01030887
Background
The benefits of exercise in the general population are well
established [1,2]. The current physical activity recom-
mendation for adults aged between 18-65 years to pro-
mote and maintain health is to accumulate at least 30
minutes of moderately intense physical activity on at least
five days of the week. Sedentary behaviour, such as time
spent sitting is positively associated with coronary heart
disease risk factors, obesity, and development of the met-
abolic syndrome [3,4]. More recently, the link between
sedentary behaviour and the development of certain can-
cer types has been reported.
Newer evidence indicates that increased physical activ-
ity after a cancer diagnosis may reduce the risk of cancer
recurrence and mortality [5-7]. Cancer survivors are at
risk of developing new primary tumours as well as sec-
ondary tumours and chronic diseases such as cardiovas-
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cular disease, osteoporosis, and diabetes [8]. This
increased risk across conditions may be genetic or treat-
ment-related but may also reflect the fact that common
life-style factors, including a sedentary lifestyle, increase
the risk for more than one disease [8].
Physical activity is also advocated during and after the
treatment for cancer. However, the adverse effects of
treatment which frequently impact on physical function-
ing and quality of life, may persist even years after treat-
ment [9-11], and must be taken into account. Many
treatments for cancer are toxic, increasing the risk for a
number of medical problems and late treatment effects
such as neuropathy [12] and cardiovascular disease [12-
14]. Cardiopulmonary capacity may also be compromised
in cancer survivors because of side effects of therapy regi-
mens such as weight gain and inactivity secondary to
treatment. The reduction in cardiopulmonary capacity
may lead to decreases in quality of life [15,16]. A down-
ward trajectory in aerobic fitness is generally observed,
possibly caused by chemotherapy and associated side-
effects such as anaemia, tachycardia, dehydration, and
cardiac dysfunction [17,18].
Other cancer survivors experience somatic symptoms
which may also persist for years after treatment such as
chronic fatigue [19,20], weight gain [19], loss of muscle
strength [21,22] and difficulty sleeping [20]. Physical and
functional well-being are essential dimensions for overall
quality of life [23], and poor physical functioning may
explain some of the psychological distress experienced by
cancer survivors [21,22].
The rationale for physical activity interventions follow-
ing cancer diagnosis includes minimizing biological pro-
cesses associated with tumour growth [24], enhancing
behavioural changes to try to minimise lifestyle risk fac-
tors for recurrence of cancer [25], and improving psycho-
social factors during and after cancer [26]. The main
physiological outcomes of physical activity after cancer
are improved fitness and physical functioning [27,28],
reduced fatigue [29], and modestly decreased weight and
body fat [30].
Even though there is strong evidence for the benefits of
physical activity aftercancer-treatment, the majority of
cancer survivors do not meet public health guidelines for
levels of physical activity necessary for health-related
benefits [31-34]. Clearly, there is a need to promote phys-
ical activity, but the optimal intervention modality, inten-
sity, training and duration are still unknown.
Many programmes in cancer rehabilitation are mainly
based on psychotherapy or social support. Such therapies
however do not usually deal with the physical problems
encountered by many patients, such as fatigue, loss of
functional capacity and weight gain [35]. Many cancer
rehabilitation programs and/or trials which include a
physical rehabilitation are lengthy in duration, extremely
intensive [36] and have tight eligibility criteria. They
would be expensive to translate into general clinical prac-
tice or to apply to the general cancer survivor population.
We have therefore devised a RCT to evaluate the effec-
tiveness and feasibility of an 8-week intervention to
improve fitness and other secondary outcomes.
Methods/Design
Study design
This will be a single-blind 2 arm pragmatic randomised
controlled trial of individually prescribed exercise in a
class setting versus usual care.
Primary aims
Outcome evaluation
To examine the effects of a supervised exercise program
commenced within 2-6 months after completion of che-
motherapy and/or radiotherapy with curative intent on
cardio-respiratory fitness, and on quality-of-life, fatigue
and morphological outcomes.
Process Evaluation
As this is a feasibility study, an additional aim is to deter-
mine the acceptability of the programme, as well as
adherence and compliance with the prescribed duration
and intensity during supervised exercise sessions.
Patient Recruitment
Participants will be sourced from the institutional cancer
database, by invitation from study personnel in cancer
clinics and directly from the oncology service in St.
James's Hospital, Dublin, Ireland. Study personnel will
provide further information to these patients and assess
them for eligibility. Ethical approval has been approved
from the institutional Research Ethics Committee and
informed consent will be gained from each participant
prior to study inclusion.
Aerobic fitness will be measured using the Modified
Bruce treadmill test and those with aerobic fitness levels
average or below age- and gender norms [37] and meet-
ing other inclusion criteria will be invited to participate in
the study. Subjects scoring average or below for age and
gender cut-off levels according to the Modified Bruce
Protocol, will be randomized to the exercise intervention
or usual care.
Inclusion criteria
(i) Diagnosis of solid tumour and completion of adjuvant
chemotherapy or radiotherapy with curative intent within
the preceding 2-6 months. Patients who have received
neoadjuvant chemotherapy or chemoradiotherapy fol-
lowed by surgery will also be eligible. Patients continuing
onto adjuvant hormone therapy and anti-Her2 directed
therapy are eligible
(ii) Ability to understand English
(iii) Willing to be randomised
(iv) Medical clearance to exercise
(v) Age 21-69Walsh et al. BMC Cancer 2010, 10:42
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(vi) Fitness level average, fair or poor according to cer-
tain pre-determined cut-off points for age and gender[37]
(vii) Willing and able to attend supervised exercise ses-
sions twice weekly for a period of 8 weeks, with an inten-
tion of achieving > 90% attendance
(viii) LVEF > 50% and not < 20% worse than baseline in
applicable patients
Exclusion criteria
(i) Evidence of active cancer
(ii) Chronic medical and orthopaedic conditions that
would preclude exercise (eg uncontrolled congestive
heart failure or angina, recent MI, breathing difficulties
requiring oxygen use or hospitalization)
(iii) On beta-blocker medication
(iii) Prior history of another cancer in previous 5 years
(exception: non-melanoma skin cancer and non-invasive
cancer of the cervix)
(iv) Confirmed pregnancy
(v) Dementia or psychiatric illness that would preclude
ability to participate in study
(vi) Incomplete haematological recovery after chemo-
therapy (WCC < 3, Hb < 10 or Platelets < 100)
(vii) BMI > 35
(viii) LVEF post chemotherapy < 50% or > 20% deterio-
r a t i o n  o f  b a s e l i n e  c o m p a r e d  t o  L V E F  b e f o r e  s y s t e m i c
treatment. LVEF criteria are applicable in patients who
have received systemic therapy (eg anthracycles, Her-2
antagonists etc) deemed in normal clinical practice to
have a potential effect LVEF and in whom the LVEF will
have been measured before systemic treatment and at
end of chemotherapy
Assessment
Post randomization follow-up will be at baseline (week 0),
end programme (8 weeks) and 3 month follow-up.
Baseline Characteristics
Cancer grade, stage, surgical management, treatment reg-
imen (chemotherapy, radiation therapy, hormonal ther-
apy) and previous medical history will be recorded by
accessing medical charts. Socio-demographic variables
recorded will include age, gender, ethnicity, employment
status, smoking, and alcohol habits accessed from medi-
cal charts and/or subjective interview.
Body Composition
Anthropometric parameters will be measured at baseline,
8 weeks and at 3 months. Body weight will be measured
to the nearest gram (g) using a standardised digital scales.
Standing height will be measured, without shoes, to the
nearest millimetre (mm) using stadiometer. BMI will be
calculated by dividing weight in kilograms by height in
metres squared.
Lean body mass will be evaluated using bioimpedence
(Tanita). Waist Circumference will be measured as per
the protocol outlined in the ACSM Resource Manual
[38].
Cardiovascular Parameters
Resting heart rate will be measured after a five minute
rest period in a seated position. Heart rate reserve will be
calculated by subtracting the resting heart rate from peak
heart rate during exercise. Oxygenation saturation will be
monitored using a finger pulse oximeter.
Blood pressure (BP) will be measured using the auscul-
tatory method in accordance with the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure guidelines.
Outcome Measures
Primary Outcome measure: Fitness Physical fitness will
be measured by the Modified Bruce Protocol. A sub-
maximal test was chosen over a maximal test for this
population because of safety and motivational concerns
[39]. Verbal encouragement during the exercise test will
be standardised.
Secondary outcomes Quality of life We will use the
FACT-G scale (general) (and the physical functional mea-
sure of the SF-36. Many uncontrollable factors influence
QOL during and after chemotherapy and a global mea-
sure of cancer-specific QOL may be too broad to detect
the likely narrower effects of exercise training, therefore a
more appropriate and realistic primary end-point in exer-
cise trials may be the functional component of QOL [40].
A statistically significant increase of greater than 4.0
points on the FACT scale represents a clinically meaning-
ful improvement in quality of life from exercise [41].
The Fact-G (version 4) is a 27-item questionnaire
divided into 4 primary QOL domains: physical well-
being, social/family well-being, emotional wellbeing, and
functional well-being and an overall quality of life level is
also yielded. The FACT-G takes about 5 minutes to com-
plete and has been written at the 6th grade level. This
questionnaire was initially developed by Cella et al. 1993
and has been validated in a mixed cancer population [42].
Patients rate all items using a 5-point rating scale ranging
from "not at all" to "very much". Strong concurrent valid-
ity is reported by strong Pearson correlations with the
Functional Living Index - Cancer (0.79) and the patient-
completed version of the QL index (0.74). Using the
global rating of change (GRC) scale as an anchor, Cella et
al proposed that a clinically meaningful change corre-
sponds to a total FACT-G raw score in the range of 5-7
points [43]. A 2008 review by Victorson et al., reported
the average reliability of the FACT-G to be 0.88 with the
reliability of subsets ranging from 0.71-0.83.
The SF-36v2 is a widely used generic measure of health
status. Psychometric properties of the SF-36 have been
well established [44]. Thirty five of the 36 items are
grouped into eight scales that address health constructs
considered to be important to most health care situa-
tions: physical functioning, role limitations (physical
problems), bodily pain, general health, vitality, socialWalsh et al. BMC Cancer 2010, 10:42
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functioning, role limitations (emotional problems), and
mental health We will use the Physical Health measure
only of the SF-36 for the purposes of this study.
Current activity level We will use the modified version
of the Godin Leisure Time Exercise Questionnaire which
has been shown to be a reliable and valid self-report mea-
sure of physical activity [45]. The questionnaire contains
three questions that assess the average frequency and
duration of mild, moderate, and strenuous exercise dur-
ing free time in a typical week Godin et al. reported the
test-retest reliability coefficient of the Godin question-
naire to be 0.64 and the concurrent validity to range from
0.38 to 0.54 over three validity criteria [45].
Accelerometry will be used to monitor 7 days of activity
at Week 0, Week 8 (immediately post intervention) & 3
months post intervention. We will use the RT3 acceler-
ometer (Stayhealthy Inc.) which has been shown to be
reliable [46] and valid [47]. The RT3 accelerometer mea-
sures activity in three dimensions. With the RT3 worn on
the hip, the vectors are as follows: vertical (x), antero-pos-
terior (y), and medio-lateral (z) and generates a summary
variable-vector magnitude.
Cancer-related fatigue We will use the 13-item Func-
tional Assessment of Chronic Illness Therapy Fatigue
Scale (FACT-Fatigue) of the Functional Assessment of
Chronic Illness Therapy measurement system which has
been developed specifically for the cancer population
[42,48]). The reliability of the FACT-fatigue scale has
been reported to be 0.84 and it has been shown to have
good validity with other measures of fatigue, a significant
negative relationship with vigor and with social desirabil-
ity [49].
Satisfaction Self-administered questionnaire on comple-
tion of programme will be administered. Participants will
also be asked to highlight what they liked about the pro-
gramme, what they didn't like, and suggestions for
change.
Demographics to be recorded Self-reported socio-
demographic variables will include age, gender, ethnicity,
employment status, smoking & alcohol habits. Medical
information will include co-morbidities and disease vari-
Table 1: Progression of the intensity & duration of the exercise class
Intensity Poor Fair Average
Week 1 35-55% HRR 40-60% HRR 45-65% HRR
21 mins aerobic 21 mins aerobic 21 mins aerobic
Week 2 35-55% HRR 40-60% HRR 45-65% HRR
24 mins aerobic 24 mins aerobic 24 mins aerobic
Week 3 40-60% HRR 45-65% HRR 50-70% HRR
24 mins aerobic 24 mins aerobic 24 mins aerobic
Week 4 40-60% HRR 45-65% HRR 50-70% HRR
30 mins aerobic 30 mins aerobic 30 mins aerobic
Week 5 45-60% HRR 50-65% HRR 55-70% HRR
30 mins aerobic 30 mins aerobic 30 mins aerobic
Week 6 45-60% HRR 50-65% HRR 55-70% HRR
36 mins aerobic 36 mins aerobic 36 mins aerobic
Week 7 50-60% HRR 55-70% HRR 65-75% HRR
36 mins aerobic 36 mins aerobic 36 mins aerobic
Week 8 50-60% HRR 55-70% HRR 65-75% aerobic
42 minutes aerobic 42 minutes aerobic 42 minutes aerobicWalsh et al. BMC Cancer 2010, 10:42
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ables such as cancer grade, stage and regimen (chemo-
therapy, radiation therapy, hormonal therapy) will be
collected from medical charts.
Additional details to be recorded Protocol deviations,
modifications made to any of the exercises will be
recoded. Safety is paramount and any adverse events will
be reported. We are aiming for a withdrawal and drop-
out rate of < 10%. Protocol deviation such as switching or
contamination, subjects dropping-out or adhering non-
perfectly will also be recorded. The following details on
compliance and adherence will also be recorded; compli-
ance (X% of exercise sessions attended and successfully
completed), adherence: we are aiming for adherence to
exercise intervention (attendance or completion of exer-
cise session) of > 70%.
Exercise Training Interventions
The class will be supervised by a physiotherapist and a
research assistant. There will be a maximum of 10 partic-
ipants in each class, giving a ratio of at most 1:5 instruc-
tor: patient ratio.
The warm-up will consist of performing the mode of
exercise prescribed for the work phase at a low intensity
to allow the cardiopulmonary system to adapt to the new
demand and to allow the temperature of the muscles to
increase. Warm-up will be 7-10 minutes duration but
slightly longer at the, initial stage of training.
Exercise intervention
The class will take 1 hour in total, with an aerobic compo-
nent of 20-40 minutes increasing on a weekly basis (Table
1). The type of exercise will be continuous, rhythmic
exercise using large muscle groups. There will be 3 aero-
bic stations: including treadmills, cycle ergometer, and
rowing machine or stepper or other aerobic exercise such
a s  m a r c h i n g  o n  t h e  s po t  d e e m e d  s u i t a b l e  b y  t h e  c l a s s
instructor.
The class frequency will be twice per week and as well
as exercise in the home environment, starting with at
least 1 other day (alternating) exercise building up to 3
other days per week. Exercise in the home environment
can be carried out in multiple sessions (but no less than
10 minutes each time). A polar watch will be worn during
these exercise sessions to monitor intensity.
Statistical analysis
Randomization will be by a computer-generated random
numbers list (GraphPad Software, San Diego, CA) with
intention-to-treat as the primary analysis and per proto-
col as the secondary analysis.
Assuming a difference of 5 mL/kg/min-1, with a SD of
6.5, and a 5% significance (two-sided) and 80% power, 28
participants would be required per group. However, the
goal would be to accrue 32 subjects to allow for a 15%
drop out rate and subgroup analyses. One year will be
allowed for accrual of participants. The drop-out rate is
calculated to include patients who are unfortunately diag-
nosed within 3 months of the final assessment as having a
relapse of their cancer. As occult return of cancer could
have a negative impact on fitness and capacity to exercise,
these patients' data will be excluded from the primary
outcome measure but included in the process analysis.
The same will be done for the data of any participant on
anti-Her2 therapy in whom an LVEF assessment during
the study or within 3 months of the end of the study has a
drop in LVEF to < 50% or by > 20% compared to baseline,
as, similarly, occult ongoing myocardial toxicity could
have a negative impact on fitness.
We will provide descriptive data and 95% CIs for all
possible comparisons. For our primary analysis, we will
use the intent-to-treat principle and for the secondary
analysis, per-protocol analysis. In sensitivity analyses
(intent-to-treat), the impact of missing values will be
studied by using a range of imputed change scores for
missing values, and by analysing those subjects who pro-
vide complete data. Repeated measured of analysis
(ANOVA) will be used across more than two time points
for continuous data. Mixed-model analysis will be used to
model each outcome measure at three (or two) time
points and compare the differences across groups over
time for non-continuous data. We will use t-tests
between 2 groups when data are normally distributed and
t h e  M a n n - W h i t n ey  U  t e s t  w i l l  be  u s e d  w h e n  d a t a  a r e
non-normally distributed. The Chi-squared test will be
used for categorical data. Tests for interaction will be car-
ried out for the effect of gender and type of cancer.
Discussion
This study will assess the effect of a novel 8-week exercise
programme in cancer survivors 2-6 months post cessa-
tion of adjuvant therapy. No intervention studies to date
have explored a relatively short individually prescribed
exercise intervention in a heterogeneous cancer popula-
tion in terms of physiological and process outcomes. This
study will provide valuable insights into the effect and
feasibility of this type of programme and if successful
would be clinically transferable to a broad range of cancer
settings.
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